Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q2

4544.TEDINET S100S6Z0
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥116.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥260.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥134.1bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income−¥1.6bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥17.7bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income−¥1.6bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥22.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥17.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥1.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥20.7bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥15.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥15.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥284.6bnat 2023-09-30Cons.Assets
Total assets¥297.9bnat 2023-03-31Cons.Assets
Total assets¥287.2bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥134.4bnat 2023-09-30Cons.Liabilities
Total liabilities¥147.9bnat 2023-03-31Cons.Liabilities
Net assets / equity¥150.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥150.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥157.2bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥37.1bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥44.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥37.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥37.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥5.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥32.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥15.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥29.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥18.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥7.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-322023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-12.332023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥275.522022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥273.872022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥175.632022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥275.52022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥273.842022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio52.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio50.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio54.7%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥2.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥72.4bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥72.3bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥74m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥6.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥33.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-09-30¥564m
—segment totalrevenue2023-04-01 → 2023-09-30¥119.6bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥116.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.2bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥85.1bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥85.0bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥83m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥40.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥35.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥15.7bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-09-30¥604m
—segment totalrevenue2022-04-01 → 2022-09-30¥139.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥134.1bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥19.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 524
ItemContextValueUnit
Retirement benefit expenses sgaPrior1YTDDuration426000000JPY
Retirement benefit expenses sgaCurrentYTDDuration458000000JPY
Depreciation sgaPrior1YTDDuration2385000000JPY
Depreciation sgaCurrentYTDDuration2706000000JPY
Amortization of goodwill sgaPrior1YTDDuration70000000JPY
Amortization of goodwill sgaCurrentYTDDuration145000000JPY
Commission fee sgaPrior1YTDDuration7402000000JPY
Commission fee sgaCurrentYTDDuration7459000000JPY
Research and development expenses sgaPrior1YTDDuration3969000000JPY
Research and development expenses sgaCurrentYTDDuration5119000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember85040000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember35224000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember13817000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember134081000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration134081000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember83000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember4991000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember10000000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember5085000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-5085000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember85123000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember40216000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember13827000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember139167000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-5085000000JPY
Net salesPrior1YTDDuration134081000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember2932000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember15709000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember604000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember19246000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-1546000000JPY
Operating incomePrior1YTDDuration17699000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember72291000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember30223000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember14028000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember116543000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration116543000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember74000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember2980000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember3000000JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember3058000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-3058000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember72366000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember33203000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember14032000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember119602000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass